Overall survival · women with persistent, recurrent, or metastatic cervical cancer
Cediranib plus chemotherapy showed no clear difference in overall survival compared with placebo plus chemotherapy (low certainty).
1 finding from 1 review
Specific adverse events: gastrointestinal perforations or fistulae · women with persistent, recurrent, or metastatic cervical cancer
It is very uncertain whether cediranib plus chemotherapy changes specific adverse events: gastrointestinal perforations or fistulae compared with placebo plus chemotherapy (very low certainty).
1 finding from 1 review
Overall survival · People with advanced non‐small cell lung cancer
TG4010 added to chemotherapy showed no clear difference in overall survival compared with chemotherapy alone (low certainty).
1 finding from 1 review
Progression‐free survival · People with advanced non‐small cell lung cancer
TG4010 added to chemotherapy may leads to lower progression‐free survival compared with chemotherapy alone (low certainty).
1 finding from 1 review
Adverse effects: at least one serious adverse event · People with advanced non‐small cell lung cancer
It is very uncertain whether TG4010 added to chemotherapy changes participants with at least one serious adverse event compared with chemotherapy alone (very low certainty).
1 finding from 1 review
Survival rates at 3 years · People with advanced non‐small cell lung cancer
TG4010 added to chemotherapy showed no clear difference in survival rates at 3 years compared with chemotherapy alone (low certainty).
1 finding from 1 review
Survival rates at 5 years · People with advanced non‐small cell lung cancer
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Health‐related quality of life · People with advanced non‐small cell lung cancer
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Overall survival (OS) · recurrent platinum‐resistant EOC
Chemotherapy with bevacizumab leads to lower overall survival (OS) compared with chemotherapy alone (high certainty).
1 finding from 1 review
Progression‐free survival · recurrent platinum‐resistant EOC
Chemotherapy with bevacizumab probably leads to lower progression‐free survival (PFS) compared with chemotherapy alone (moderate certainty).
1 finding from 1 review
Quality of life · recurrent platinum‐resistant EOC
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Adverse events (grade ≥ 3) · recurrent platinum‐resistant EOC
Chemotherapy with bevacizumab showed no clear difference in any adverse event grade ≥ 3 compared with chemotherapy alone (low certainty).
1 finding from 1 review
Hypertension (grade ≥ 2) · recurrent platinum‐resistant EOC
Chemotherapy with bevacizumab may leads to higher hypertension (grade ≥ 2) compared with chemotherapy alone (low certainty).
1 finding from 1 review
Bowel fistula / perforation (grade ≥ 2) · recurrent platinum‐resistant EOC
Chemotherapy with bevacizumab showed no clear difference in bowel fistula / perforation (grade ≥ 2) compared with chemotherapy alone (low certainty).
1 finding from 1 review
Overall survival · women with persistent, recurrent, or metastatic cervical cancer
Bevacizumab plus chemotherapy may leads to lower overall survival compared with chemotherapy (low certainty).
1 finding from 1 review
Specific adverse events: gastrointestinal perforations or fistulae · women with persistent, recurrent, or metastatic cervical cancer
Bevacizumab plus chemotherapy probably leads to higher specificadverse events: gastrointestinal perforations or fistulae compared with chemotherapy (moderate certainty).
1 finding from 1 review
Specific adverse events: serious haemorrhage · women with persistent, recurrent, or metastatic cervical cancer
Bevacizumab plus chemotherapy may leads to higher specific adverse events: serious haemorrhage compared with chemotherapy (low certainty).
1 finding from 1 review
Specific adverse events: serious thromboembolic events · women with persistent, recurrent, or metastatic cervical cancer
Bevacizumab plus chemotherapy probably leads to higher specific adverse events: serious thromboembolic events compared with chemotherapy (moderate certainty).
1 finding from 1 review
Adverse events: hypertension · women with persistent, recurrent, or metastatic cervical cancer
Bevacizumab plus chemotherapy probably leads to higher specific adverse events: hypertension compared with chemotherapy (moderate certainty).
1 finding from 1 review
Serious adverse events · women with persistent, recurrent, or metastatic cervical cancer
Bevacizumab plus chemotherapy probably leads to higher serious adverse events compared with chemotherapy (moderate certainty).
1 finding from 1 review